Rite Aid (RAD) Misses Q1 EPS by 4c

Rite Aid (NYSE: RAD) reported Q1 EPS of $0.01, $0.04 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $8.18 billion versus the consensus estimate of $8.26 billion.

Adjusted EBITDA was $286 million.

Same store sales for the quarter increased 0.4 percent over the prior year, consisting of a 0.1 percent increase in pharmacy sales and a 1.2 percent increase in front-end sales. Pharmacy sales included an approximate 198 basis point negative impact from new generic introductions. The number of prescriptions filled in same stores increased 0.6 percent over the prior year period. Prescription sales accounted for 68.9 percent of total drugstore sales, and third party prescription revenue was 98.0 percent of pharmacy sales.

For earnings history and earnings-related data on Rite Aid (RAD) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
• OLB Group narrows net loss 50% as revenue falls in Q2 2026